Predict your next investment

Private Equity
nmtcapital.com

See what CB Insights has to offer

Investments

33

Portfolio Exits

14

About Nexus Medical Partners

Nexus Medical Partners, (NMT Capital ) is a global private equity firm specializing in making private equity investments in and providing strategic assistance to medical technology and selected life science companies.

Nexus Medical Partners Headquarter Location

400 Crown Colony Drive Suite 104

Quincy, Massachusetts, 02169,

United States

617-472-2805

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nexus Medical Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Nexus Medical Partners in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

G

Game Changers 2019

196 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

Latest Nexus Medical Partners News

Selah Genomics Inc Announces Management Buy-out of Lab21 Inc

Jan 8, 2013

January 08, 2013 12:06 PM Eastern Standard Time GREENVILLE, S.C.--( BUSINESS WIRE )--Selah Genomics Inc announces the completion of its management buy-out of Lab21 Inc, the US subsidiary of Lab21 Ltd, led by the existing Lab21 Inc management team. Nexus Medical Partners, SCRA Technology Ventures’ Stage 2 Affiliate, SC Launch and the Greenville Local Development Corporation supported the buyout. Nexus Medical Partners Co-Founders Ed Snape and John Rousseau will join Michael Bolick on the Selah Genomics board. John Rousseau said: “Selah Genomics performs genetic testing in laboratories regulated by the U.S. Center for Medicare & Medicaid Services under the Clinical Laboratory Improvement Amendments (CLIA). Selah is leveraging the latest in molecular and genomic technologies to develop companion diagnostics, i.e., tests that can tell doctors when a specific patient has a DNA mutation that can be targeted by a drug. We look forward to working with the Selah team in this exciting period for the company as we continue to grow our South Carolina-based portfolio.” Michael Bolick, CEO of Selah Genomics comments: “Having been President of Lab21 Inc for the last three years, I am genuinely excited by the opportunity to lead Selah as we expand our molecular diagnostic testing services from our main CLIA laboratory in downtown Greenville SC and from our first Clinical Genomics Center, which is physically located within the Greenville Health System’s Institute for Translational Oncology Research (ITOR). Our team is uniquely suited to help advance the genomics revolution into research labs and clinical trials where drugs are being designed and developed to home in on the specific molecular drivers of disease. We have a number of exciting developments under way and look forward to a strong 2013.” Bill Mahoney, CEO of SCRA, said: “Selah is a diagnostics company at the forefront of bringing comprehensive genomic analysis to the clinic. This change in the management of patient care through the use of more precise diagnostic tests is an exciting development. Selah’s proven skill in determining the genetic profile of patient samples is vital to today’s clinical trials and the development of companion diagnostics. We are thrilled to see this continued growth for one of our leading SC Launch and now Stage 2 portfolio companies.” About Nexus Medical Partners Nexus Medical Partners is a private equity firm, headquartered in Boston, MA, specializing in making private equity investments in and providing strategic assistance to medical technology and selected life science companies. About SCRA and SCRA Technology Ventures SCRA Technology Ventures helps innovative companies grow and develop new technologies, creating jobs and advancing the Knowledge Economy throughout South Carolina. This SCRA business sector provides support and mentoring through its flagship SC Launch program to early stage, start-up technology companies. Since 2006, SCRA has deployed over $59 million in funding and infrastructure to support over 280 high -tech, early-stage enterprises, and has directly invested over $13 million in South Carolina start-ups, attracting over $200 million in private investment. SCRA Technology Ventures also supports commercialization and growth by facilitating the transfer of intellectual property and accelerating the transition of inventions to the marketplace. Additionally, SCRA Technology Ventures invests in more established technology companies through its Stage 2 affiliate. Contacts

Nexus Medical Partners Investments

33 Investments

Nexus Medical Partners has made 33 investments. Their latest investment was in KIYATEC as part of their Series B - II on February 2, 2019.

CBI Logo

Nexus Medical Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/22/2019

Series B - II

KIYATEC

$3M

No

2

3/27/2013

Series B

Spectra Analysis Instruments

$1.35M

No

1

5/24/2012

Private Equity - II

Spectra Analysis Instruments

$0.67M

No

5/11/2012

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/21/2012

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2019

3/27/2013

5/24/2012

5/11/2012

3/21/2012

Round

Series B - II

Series B

Private Equity - II

Series A

Series D

Company

KIYATEC

Spectra Analysis Instruments

Spectra Analysis Instruments

Subscribe to see more

Subscribe to see more

Amount

$3M

$1.35M

$0.67M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

10

10

Nexus Medical Partners Portfolio Exits

14 Portfolio Exits

Nexus Medical Partners has 14 portfolio exits. Their latest portfolio exit was Presidio Bank on October 14, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/14/2019

Acq - P2P

4

3/5/2019

Acquired

$991

3

7/17/2017

Acquired

$991

5

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/14/2019

3/5/2019

7/17/2017

00/00/0000

00/00/0000

Exit

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

3

5

10

10

Nexus Medical Partners Acquisitions

1 Acquisition

Nexus Medical Partners acquired 1 company. Their latest acquisition was Selah Genomics on January 09, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/9/2013

Management Buyout - II

$0.75M

Management Buyout

1

Date

1/9/2013

Investment Stage

Management Buyout - II

Companies

Valuation

Total Funding

$0.75M

Note

Management Buyout

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.